FDA approves Tretten for Congenital factor XIII deficiency-Novo Nordisk
Novo Nordisk announced the FDA has on 23 December 2013 approved Tretten (Coagulation Factor XIII A-Subunit [Recombinant]) for the routine prophylaxis of bleeding in people with congenital factor XIII (FXIII) A-subunit deficiency. Tretten is the only recombinant treatment for congenital FXIII A-subunit deficiency � a serious, rare bleeding disorder with limited treatment options. Tretten demonstrated safety and efficacy, offering patients once-monthly dosing with a short infusion time.
Treteen is also approved in Canada as Tretten as well as in the EU, Switzerland and Australia as NovoThirteen.
.Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins